Investing in SA pays off for pharmaceutical company

Belief, determination and patience are the key ingredients that a pharmaceutical company invested in South Africa has consistently used over the years.

The recipe continues to work for B. Braun, which has found South Africa to be a profitable investment destination. The company, which is headquartered in Germany, has had a presence in South Africa since 1995.

“We believe in the future of South Africa. The main target is to produce products at the highest quality standards and to bring the cost down as much as possible merely through productivity and efficiency. This was the mission when we pursued this investment,” says B. Braun Managing Director for Southern Africa, Jens Papperitz.

His comments come ahead of the fourth South African Investment Conference (SAIC).

In 2019, B. Braun pledged to invest R300 million at the SAIC. This was to expand its capabilities, tripling its manufacturing volume, where a significant portion was to be produced for exports.

The investment was spent on the construction of a new state-of-the-art facility that has united the production of intravenous sterile products, dialysis concentrates and disinfectants.

Creating jobs

As a result, the company created employment for about 160 people at its integrated pharmaceutical plant, situated in the Longlake Business Park in Modderfontein, Johannesburg.

The construction of the plant saw the creation of between 500 and 1000 job opportunities.

The majority of the new employees, who live in the nearby township of Alexandra, were recruited through the Youth Employment Service (YES) programme.